动脉粥样硬化性心血管疾病风险评估对中国高血压防治的启示

The risk assessment of atherosclerotic cardiovascular disease and its inspiration for prevention and treatment of hypertension in China

高血压是心脑血管疾病最为重要的危险因素之一.对高血压患者进行动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)风险评估是临床工作中不可忽视的重要环节.目前我国常用的风险评估模型主要有美国心脏病学会(American College of Cardiology,ACC)/美国心脏协会(American Heart Association,AHA)制定的汇总队列公式模型(pooled cohort equations,PCE)、Framingham心血管疾病风险评估模型(Framingham risk score,FRS)和中国缺血性心血管疾病(ischemic cardiovascular disease,ICVD)风险评估模型(Prediction for ASCVD risk in China,China-PAR).三者在纳入人群、终点事件、计算方法等方面既有相似又有不同,各自之间既有优势又有不足.本文对三种模型的特点以及临床应用进行了综述.

Hypertension is one of the most important risk factors for cardiovascular and cerebrovascular diseases. The risk assessment of atherosclerotic cardiovascular disease (ASCVD) in patients with hypertension is an important part of clinical work. At present, the risk assessment models commonly used in China mainly include the pooled cohort equations (PCE) developed by the American College of Cardiology (ACC)/American Heart Association (AHA ), the Framingham cardiovascular disease risk assessment model (FRS) and China's ischemic cardiovascular disease(ICVD) risk assessment model (China-PAR). The three are similar and different in terms of inclusion, end-point events and calculation methods;and each has its own advantages and disadvantages. The article reviews the characteristics and clinical applications of the three nlodels.